Analyse de l'ultrafiltration pendant la stase longue sous icodextrine en dialyse péritonéale automatisée
DOI :
https://doi.org/10.25796/bdd.v8i1.86303Mots-clés :
Dialyse péritonéale, Dialyse péritonéale automatisée, Insuffisance rénale chronique, Icodextrine, Maladie rénale chronique, Pression intra-péritonéale, UltrafiltrationRésumé
Les propriétés osmotiques uniques de l'icodextrine permettent une gestion efficace des volumes de liquide dans la cavité péritonéale en limitant la réabsorption. Toutefois, des variations persistent lors de périodes de stase prolongée en dialyse péritonéale automatisée (DPA), ce qui constitue un défi clinique et accroît le risque d'échec de traitement. Cette étude vise à examiner les phénomènes d'ultrafiltration (UF) négative durant la stase diurne chez les patients en DPA sous icodextrine, ainsi qu'à identifier les facteurs associés à cette occurrence. Une étude rétrospective observationnelle monocentrique sur l'UF réalisée pendant les périodes de stase prolongée d'icodextrine en DPA a été menée auprès de 27 patients incidents au Centre Hospitalier Universitaire de Caen en Normandie, France. L'événement principal était la présence d'une UF diurne négative, avec la pression intrapéritonéale (PIP) comme variable d'exposition. Les analyses statistiques, y compris des comparaisons entre groupes, des régressions logistiques univariées et multivariées, ont été réalisées. Bien que la corrélation entre les variables et l'UF diurne négative n'ait pas été significative, la PIP (OR=1,06), le Volume de la dernière injection (OR=0,97) et l'Indice de Masse Corporelle (OR=0,97) présentent des tendances intéressantes. L'analyse multivariée n'a pas révélé d'association significative entre les variables et l'UF diurne négative. Néanmoins, la PIP s'est avérée être la seule variable à améliorer la qualité du modèle, suggérant un lien potentiel qui nécessite une exploration plus approfondie. Malgré le fait que la mesure de la PIP ne soit pas systématique dans les centres de dialyse, cette étude suggère ses avantages en cas de variabilité de l'UF sous DPA, soulevant ainsi des questions importantes pour la recherche future et la pratique clinique. Les limites de l'étude, notamment la taille restreinte de l'échantillon et la nature observationnelle rétrospective de la méthodologie, affectent la puissance statistique et la possibilité d'établir des liens de causalité.
Introduction
In 2022, only 6% of patients in stage 5 chronic kidney disease (CKD) in France were treated with peritoneal dialysis (PD), which highlights its relatively low adoption rate[1]. Automated peritoneal dialysis (APD), however, remains a cornerstone therapy for managing end-stage kidney disease (ESKD), offering flexibility and effectiveness in achieving fluid and solute clearance[2][3][4][5][6]. APD provides several benefits, particularly for patients requiring urgent initiation of dialysis, as it has been associated with a lower incidence of PD-related complications compared to urgent start of hemodialysis[7].
However, challenges persist in the effective use of APD, particularly in addressing negative daytime ultrafiltration (UF) when icodextrin is used[8][9][10][11]. Icodextrin, a complex polysaccharide solution, is widely used in PD for its ability to sustain UF during long daytime dwell periods and reduce glucose-related complications[11][12][13][14][15][16]. Nonetheless, negative UF or UF failure during the long dwell remains a significant clinical challenge, potentially leading to fluid overload and associated morbidities[8][10][11].
According to the International Society for Peritoneal Dialysis (ISPD), UF failure is defined as a net UF of less than 400 mL after a 4-hour dwell with glucose/dextrose 3.86%/4.25%, or less than 100 mL with glucose/dextrose 2.27%/2.5%[17]. Several factors contribute to UF variation under icodextrin, including patient membrane characteristics, hydrostatic and osmotic pressures, dialysate composition, and metabolic factors [8–10,18,19]. Lambie et al[8]closely examined these influences, emphasizing the importance of individualized management.
Another critical factor can be the intraperitoneal pressure (IPP), the pressure exerted within the abdominal cavity[20]. IPP is influenced by factors such as the volume of fluid in the peritoneal cavity, patient morphology, posture, and abdominal muscle tone [21,22][21][22]. IPP measurement, first described by Durand et al.[22][23][24]in the 1990s, is a simple and non-invasive procedure. It involves placing the patient in a supine position and estimating the pressure by measuring the height of the dialysate column in tubing connected to the catheter, using the mid-axillary line as the reference point[22][23][24]. For a patient in a supine position, IPP typically ranges between 8 and 18 cmH2O for an infused peritoneal volume of 2 L[23][24].
Our study aimed to analyze the occurrence of negative daytime UF during icodextrin long dwell in patients undergoing APD, focusing specifically on this occurrence and identifying potential associated factors.
Materials and methods
Study population
This retrospective, observational, monocentric study was conducted in the Nephrology Department at the University Hospital of Caen in Normandy, France. It included all adult incident patients undergoing PD at our center from August 31, 2018, when systematic IPP measurement was initiated, until September 12, 2022. The study focused on patients who received APD treatment for at least six months after starting PD. Exclusion criteria comprised patients with an APD duration of less than 30 days or those who initiated APD more than six months after starting PD.
Definition of variables
Patient characteristics included in the study were obtained from the French Language Peritoneal Dialysis Registry, RDPLF. The following variables were extracted: age, gender, initial nephropathy, modified Charlson index (mCCI), diabetic status, weight, and height.
Dialysis prescriptions were sourced from medical records and included the following variables: total dialysis volume, volume per cycle, volume of the last injection, total dialysis duration, dwell time per cycle, daytime dwell duration, number of nighttime cycles, use of hypertonic solution, use of icodextrin, and the percentage of icodextrin used, when applicable. Additionally, data on residual diuresis volume, IPP measurements, and the dates and results of the first peritoneal equilibration test (PET) and first clearance were collected.
Peritoneal dialysis outcomes were retrieved from the monitoring sheets for the first week of the second month of PD for patients included in the study, using Renalsoft® and Sharesource® software. The extracted variables included daytime, nighttime, and 24-hour UF, dwell time per cycle, daytime dwell duration, total per-cycle volume, and daytime dwell volumes. These variables were collected over the seven days leading up to the extraction and averaged, based on the assumption that this averaging would correct for variability within patients.
Events of interest
The primary outcome of interest was the occurrence of negative daytime UF, defined as an average daytime UF of less than 0 during the data extraction week. Patients included in the study were categorized based on the presence or absence of negative daytime UF (yes/no).
Explanatory variables
The primary exposure variable was IPP, measured in cm of H2O with a 2 liter intraperitoneal dwell. At our center, IPP is routinely measured on the fourth day of patient training, prior to the initiation of PD. This measurement has been systematically performed since August 31, 2018, marking the start of patient inclusions in this study. The IPP measurement protocol adheres to the guidelines set forth by the ISPD[17].
Statistical Analysis
Linear variables were summarized using medians and interquartile ranges (IQR), while categorical variables were reported as frequencies and percentages. Patients were categorized based on the primary outcome, namely daytime UF, a binary qualitative variable with negative or positive classifications.
For further exploration of the association between negative daytime UF (the primary event of interest), IPP (the primary exposure variable), and other relevant exposure variables, graphical representations and univariate logistic regression analyses were performed. Each variable was analyzed separately in
Références
1. Thierry Vignolles. Les Chiffres Clés de La Maladie Rénale. https://www.francerein.org/actualites/les-chiffres-cles-de-la-maladie-renale/ (2022).
2. Mehrotra, R., Devuyst, O., Davies, S. J., & Johnson, D. W. (2016). The Current State of Peritoneal Dialysis. Journal of the American Society of Nephrology : JASN, 27(11), 3238–3252. https://doi.org/10.1681/ASN.2016010112
3. Lanot, A, Lobbedez, T. Place et utilisation de la dialyse péritonéale dans le traitement de l’insuffisance rénale chronique terminale. Nephrologie 34, 1–18 (2022).
4. Boyer, A., Lanot, A., Béchade, C., & Lobbedez, T. (2022). La dialyse péritonéale : ce que le réanimateur doit savoir. Médecine Intensive Réanimation, 32(1), 85–98. https://doi.org/10.37051/mir-00134
5. Auguste, B. L., & Bargman, J. M. (2023). Peritoneal Dialysis Prescription and Adequacy in Clinical Practice: Core Curriculum 2023. American journal of kidney diseases : the official journal of the National Kidney Foundation, 81(1), 100–109. https://doi.org/10.1053/j.ajkd.2022.07.004
6. Blake P. G. (2008). Peritoneal dialysis: a «kinder,gentler» treatment for the elderly?. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 28(5), 435–436.
7. Jin, H., Fang, W., Wang, L., Zang, X., Deng, Y., Wu, G., Li, Y., Chen, X., Wang, N., Jiang, G., Guo, Z., Wang, X., Qi, Y., Lv, S., & Ni, Z. (2024). A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRD. Kidney international reports, 9(9), 2627–2634. https://doi.org/10.1016/j.ekir.2024.06.032
8. Lambie, M., Stompor, T., & Davies, S. (2009). Understanding the variability in ultrafiltration obtained with icodextrin. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 29(4), 407–411.
9. Mujais, S. et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 20 Suppl 4, S5-21 (2000).
10. Venturoli, D., Jeloka, T. K., Ersoy, F. F., Rippe, B., & Oreopoulos, D. G. (2009). The variability in ultrafiltration achieved with icodextrin, possibly explained. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 29(4), 415–421.
11. Silver, S. A., Harel, Z., & Perl, J. (2014). Practical considerations when prescribing icodextrin: a narrative review. American journal of nephrology, 39(6), 515–527. https://doi.org/10.1159/000363417
12. Frampton J. E., Plosker G. L. & Bredie S. J. H. Icodextrin: a review of its use in peritoneal dialysis. Adis Drug Evaluation 63, 2079–2105 (2003).
13. Ahmad, M., Jeloka, T., Pliakogiannis, T., Tapiawala, S., Zhong, H., Bargman, J. M., & Oreopoulos, D. (2008). Icodextrin produces higher ultrafiltration in diabetic than in non-diabetic patients on continuous cyclic peritoneal dialysis. International urology and nephrology, 40(1), 219–223. https://doi.org/10.1007/s11255-007-9298-3
14. Paniagua, R., Ventura, M. D., Avila-Díaz, M., Cisneros, A., Vicenté-Martínez, M., Furlong, M. D., García-González, Z., Villanueva, D., Orihuela, O., Prado-Uribe, M. D., Alcántara, G., & Amato, D. (2009). Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 29(4), 422–432.
15. Jeloka, T. K., Ersoy, F. F., Yavuz, M., Sahu, K. M., Camsari, T., Utaş, C., Bozfakioglu, S., Ozener, C., Ateş, K., Ataman, R., Akçiçek, F., Akpolat, T., Karayaylali, I., Arinsoy, T., Mehmet, E. Y., Süleymanlar, G., Burdzy, D., & Oreopoulos, D. G. (2006). What is the optimal dwell time for maximizing ultrafiltration with icodextrin exchange in automated peritoneal dialysis patients?. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 26(3), 336–340.
16. Qi, H., Xu, C., Yan, H., & Ma, J. (2011). Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 31(2), 179–188. https://doi.org/10.3747/pdi.2009.00264.
17. Morelle, J., Stachowska-Pietka, J., Öberg, C., Gadola, L., La Milia, V., Yu, Z., Lambie, M., Mehrotra, R., de Arteaga, J., & Davies, S. (2021). ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: Classification, measurement, interpretation and rationale for intervention. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 41(4), 352–372. https://doi.org/10.1177/0896860820982218
18. Imholz, A. L., Koomen, G. C., Struijk, D. G., Arisz, L., & Krediet, R. T. (1993). Effect of an increased intraperitoneal pressure on fluid and solute transport during CAPD. Kidney international, 44(5), 1078–1085. https://doi.org/10.1038/ki.1993.351.
19. Krediet, R., & Mujais, S. (2002). Use of icodextrin in high transport ultrafiltration failure. Kidney international. Supplement, (81), S53–S61. https://doi.org/10.1046/j.1523-1755.62.s81.8.x
20.Castellanos, L. B., Clemente, E. P., Cabañas, C. B., Parra, D. M., Contador, M. B., Morera, J. C. O., & Daly, J. A. (2017). Clinical Relevance of Intraperitoneal Pressure in Peritoneal Dialysis Patients. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 37(5), 562–567. https://doi.org/10.3747/pdi.2016.00267
21.Dejardin, A., Robert, A., & Goffin, E. (2007). Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PD-related complications. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 22(5), 1437–1444. https://doi.org/10.1093/ndt/gfl745 22. Durand P. Y., Chanliau J., Gamberoni J., Hestin D. & Kessler, M. Routine measurement of hydrostatic intraperitoneal pressure. Adv Perit Dial 8, 108–12 (1992).
23. Sobrino-Pérez, A., Pérez-Escudero, A., Fernández-Arroyo, L., Dorado-García, A., Martín-Alcón, B., Gutiérrez-Martín, C., Sánchez-Fonseca, C., Barrios-Rebollo, C., Pérez-Díaz, V., & Group PIPDPCyL (2021). Intraperitoneal pressure: Stability over time and validation of Durand’s measurement method. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 41(4), 427–431. https://doi.org/10.1177/0896860820973120
24. Durand, P. Y., Chanliau, J., Gambéroni, J., Hestin, D., & Kessler, M. (1996). Measurement of hydrostatic intraperitoneal pressure: a necessary routine test in peritoneal dialysis. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 16 Suppl 1, S84–S87.
25. Pérez Díaz, V., Sanz Ballesteros, S., Hernández García, E., Descalzo Casado, E., Herguedas Callejo, I., & Ferrer Perales, C. (2017). Intraperitoneal pressure in peritoneal dialysis. La presión intraperitoneal en diálisis peritoneal. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 37(6), 579–586. https://doi.org/10.1016/j.nefro.2017.05.014
26. Ferreira A. C. (2023). Intraperitoneal pressure in peritoneal dialysis patients: a need for treatment individualization. Clinical kidney journal, 16(9), 1367–1368. https://doi.org/10.1093/ckj/sfad140
Téléchargements
Soumis
Accepté
Publié
Comment citer
Numéro
Rubrique
Licence
© Tara Srouji 2025

Ce travail est disponible sous la licence Creative Commons Attribution 4.0 International .







